<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04279496</url>
  </required_header>
  <id_info>
    <org_study_id>Confirm2-Registry</org_study_id>
    <nct_id>NCT04279496</nct_id>
  </id_info>
  <brief_title>Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry</brief_title>
  <acronym>CONFIRM2</acronym>
  <official_title>Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cleerly, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cleerly, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of CONFIRM2 is to perform the largest cardiovascular phenotype outcomes
      study ever.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CONFIRM2 is a retrospective and prospective, open-label, international, multicenter
      observational registry designed to evaluate associations between CCTA imaging findings and
      clinical presentation (cross-sectional) and their ability to predict mortality and major
      adverse cardiac events (longitudinal) in patients with chronic CAD.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>6 Years</target_duration>
  <primary_outcome>
    <measure>Coronary CT Angiography EvaluatioN For Clinical Outcomes</measure>
    <time_frame>June 2020- June 2022</time_frame>
    <description>Examined the totality of information visualized by coronary CT angiography (CCTA) for optimal refinement of prognostic risk stratification</description>
  </primary_outcome>
  <enrollment type="Anticipated">35000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with stable coronary artery disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Undergoing clinically indicated CCTA with &gt;64-detector row CT

          -  Signed informed consent, including of release of medical information, long term
             follow-up and Health Insurance Portability and Accountability Act (HIPAA)
             documentation

        Exclusion Criteria:

          -  Individuals unable to provide informed consent

          -  Non-cardiac illness with life expectancy &lt; 2 years

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James K Min, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cleerly, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Todd Villines, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UVA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tiffany Brown</last_name>
    <phone>6463624255</phone>
    <email>tiffany.brown@cleerlyhealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jamie Stern, MBA/MS</last_name>
    <phone>5164565531</phone>
    <email>jamie.stern@cleerlyhealth.com</email>
  </overall_contact_backup>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 19, 2020</study_first_submitted>
  <study_first_submitted_qc>February 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2020</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

